Mr. Marc-Andre Massue reports

DIAGNOS ANNOUNCES VOTING RESULTS OF MEETING OF SHAREHOLDERS

Diagnos Inc. has released the voting results of its annual general and special meeting of shareholders held on Sept. 25, 2024.

Election of directors

The following directors were elected to hold office until the closing of the next annual meeting of the shareholders: Andre Larente, Francis Bellido, Robert Dunn, Michael Braeuel and Philippe Couillard.

Appointment of auditor

Raymond Chabot Grant Thornton LLP was re-appointed as auditor of the Corporation for the ensuing year.

Amendment to the stock option plan

The shareholders of the corporation approved a special resolution pursuant to which the maximum number of common shares of the corporation that may be issued under the stock option plan be set at 12.2 million, representing an increase of two million common shares.

Some of the provisions of the plan were amended to comply with the current version of Policy 4.4 of the TSX Venture Exchange. Please refer to the 2024 management information circular of the corporation available on SEDAR+ for the updated version of the plan.

the amendments to the plan remain subject to TSX-V acceptance.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modification and development of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.